Roman A. Ivanov is currently the Vice Rector at the Sirius University of Science and Technology, Russia. He completed his Ph.D. in Molecular Immunology at the Utrecht University, the Netherlands in 2005. He has more than 13 years of both scientific and executive experience in a biopharmaceutical company as well as 4.5 years of fundamental research in immunology and molecular biology. From 2005 to 2019, he led the development of BIOCAD—the largest Russian biotech company—first as medical director and then as vice president for research and development—and supervised the creation of biosimilar and original monoclonal antibody-based drugs. His research areas include the development of innovative small-molecule drugs, the development of mRNA vaccine platforms, the development of novel platforms for the production of peptide-based therapeutics, and the search for novel medicines to overcome and prevent resistance to antibiotics.